Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Emphasis on Aggressive Cancer Cells
R
Richard Godfrey
CEO
BerGenBio ASA
Aug 16, 2017
PTV-M06-17-BIO-009
Oncology
PA TV (video)
Richard Godfrey, CEO, BerGenBio ASA
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About Us
Nice Insight
That's Nice
Reach Our Team
Contact Us
Advertise
LinkedIn
My Account
Login
Sign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy Policy
Terms And Conditions
Related Content
Rare Cancer CGT
Developing Cell and Gene Therapies for Rare Oncology Applications
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-10
Jul 16, 2026
Tumor-Agnostic
Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-05
Jul 8, 2026
Basket Trials
Basket Trials and the Future of Rare Cancer Research
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-02
Jul 2, 2026
Organoids
Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research
Seahee Kim, Ph.D.
Samsung Biologics
PAO-06-26-CL-04
Jul 1, 2026
Research Collab
10x Genomics and Cleveland Clinic Collaborate in Diagnostic Applications of Single Cell and Spatial Technologies in Bladder Cancer
10x Genomics
PR-06-26-02
Jun 17, 2026
Ovarian Cancer
Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer
David Alvaro, Ph.D.; Jason Litten, M.D.
Pharma's Almanac
PAO-04-26-CL-03
Apr 21, 2026
Ovarian Cancer
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
Ernexa Therapeutics
PR-01-26-01
Jan 6, 2026
Inducement Grants
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals
PR-10-25-NI-04
Oct 3, 2025
Collaboration
TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer
Tegmine Therapeutics
PR-09-25-NI-05
Sep 23, 2025
Cancer Vaccine
Cleveland Clinic to Present Final Phase 1 Results for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Symposium
Anixa Biosciences
PR-09-25-NI-03
Sep 22, 2025
ADCs
Improved Efficacy and Safety Driving Resurging Interest in ADCs
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-09-25-NI-05
Sep 22, 2025
Ovarian Cancer
Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-25-NI-03
Sep 10, 2025
Previous slide
Next slide
